Assessing the therapeutic and toxicological profile of novel GLP-1 receptor agonists for type 2 diabetes

2024-9-13

Clinical pharmacokinetics of glipizide: a systematic review

2024-9-12

Intraocular drugs: pharmacokinetic strategies and the influence on efficacy and durability

2024-9-11

A pharmacokinetic and pharmacodynamic evaluation of asundexian: a novel factor XIa inhibitor for stroke prevention

2024-9-11

Drug interactions in cardiology: focus on statins and their combination with other lipid-lowering drugs

2024-9-9

<i>In vitro</i> neurotoxicity testing: lessons from chemotherapy-induced peripheral neurotoxicity

2024-9-9

Pharmacokinetics of S1P receptor modulators in the treatment of ulcerative colitis

2024-9-9

Unraveling Ritlecitinib: an in-depth analysis of JAK3 inhibitor for the treatment of alopecia areata

2024-9-9

Clinical pharmacokinetics and pharmacodynamics of Nicardipine; a systematic review.

2024-9-9

Pharmacokinetics and pharmacodynamics of angiogenesis inhibitors used to treat cervical cancer: current and future

2024-9-9

Analysis of drug-drug interactions in patients with HIV and metabolic syndrome

2024-9-4

Underlying mechanisms and management strategies for regorafenib-induced toxicity in hepatocellular carcinoma

2024-9-3

Milvexian a novel factor XIa inhibitor for stroke prevention: pharmacokinetic and pharmacodynamic evaluation

2024-8-30

Cardiometabolic complications in children and adolescents with HIV on antiretroviral therapy

2024-8-30

Analgesic medication considerations for chronic pain management post-bariatric surgery

2024-8-28

Safety of potassium-competitive acid blockers in the treatment of gastroesophageal reflux disease

2024-8-27

Development and application of a population pharmacokinetic model repository for caffeine dose tailoring in preterm infants

2024-8-21

Physiologically based pharmacokinetic modeling in obesity: applications and challenges

2024-8-12

Clinical pharmacokinetics of cefpodoxime: a systematic review

2024-8-9

Pharmacokinetics of aspirin: evaluating shortcomings in the literature

2024-8-2

Dose optimization of β-lactam antibiotics in children: from population pharmacokinetics to individualized therapy

2024-8-1

Population pharmacokinetics of olanzapine in pediatric patients with psychiatric disorders

2024-7-23

Population toxicokinetics of carbamazepine and its metabolite carbamazepine-10,11-epoxide in adults

2024-7-18

An update on oral antiplatelet drug interactions with proton pump inhibitors: what are the risks?

2024-7-15

How can we better address the pharmacokinetics of antipsychotics in children and adolescents?

2024-7-9

Recent progress in adverse events of carboxylic acid non-steroidal anti-inflammatory drugs (CBA-NSAIDs) and their association with the metabolism: the consequences on mitochondrial dysfunction and oxidative stress, and prevention with natural plant extracts

2024-7-9

Proposing a novel approach for the long-term use of monthly paliperidone palmitate: adjusting injection dose versus adjusting injection interval

2024-7-9

Machine learning and deep learning approaches for enhanced prediction of hERG blockade: a comprehensive QSAR modeling study

2024-7-5

Pharmacokinetic evaluation of ibrexafungerp for the treatment of vulvovaginal candidiasis and beyond

2024-7-3

Investigating in VigiBase® over 6000 cases of pneumonia in clozapine-treated patients in the context of the literature: focus on high lethality and the association with aspiration pneumonia

2024-7-2

Screening tools to evaluate the neurotoxic potential of botanicals: building a strategy to assess safety

2024-7-2

Overview of preclinical and clinical studies investigating pharmacokinetics and drug–drug interactions of padsevonil

2024-6-27

Pharmacokinetic review of janus kinase inhibitors and its clinical implications for the management of rheumatoid arthritis

2024-6-25

Investigative analysis of blood-brain barrier penetrating potential of electronic nicotine delivery systems (e-cigarettes) chemicals using predictive computational models

2024-6-17

Bioengineered human gut-on-a-chip for advancing non-clinical pharmaco-toxicology

2024-6-8

An update on microfluidic multi-organ-on-a-chip systems for reproducing drug pharmacokinetics: the current state-of-the-art

2024-6-2

Recent advances in cell-based in vitro models for predicting drug permeability across brain, intestinal, and pulmonary barriers

2024-6-2

Pharmacokinetics, pharmacodynamics, safety, and tolerability of dopamine-receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting

2024-6-2

Understanding the impact of ABCG2 Polymorphisms on Drug Pharmacokinetics:Focus on rosuvastatin and allopurinol

2024-5-29

Genetic polymorphisms of drug-metabolizing enzymes in older and Newer Anti-Seizure Medications

2024-5-29

Recent progress in machine learning approaches for predicting carcinogenicity in drug development

2024-5-27

New-generation androgen receptor signaling inhibitors (ARSIs) in metastatic hormone-sensitive prostate cancer (mHSPC): pharmacokinetics, drug-drug interactions (DDIs), and clinical impact

2024-5-22

The role of the circadian timing system on drug metabolism and detoxification: an update

2024-5-20

Pharmacokinetic evaluation of Donanemab for the treatment of Alzheimer’s

2024-5-18

Pharmacokinetic and toxicological considerations affecting antiretroviral drug dosing in pregnant women

2024-5-14

Induction effect of antiretroviral bictegravir on the expression of Abcb1, Abcg2 and Abcc1 genes associated with P-gp, Bcrp and Mrp1 transporters present in rat peripheral blood mononuclear cells

2024-5-13

New approach methods on the bench side to accelerate clinical trials during pregnancy

2024-5-13

In NAMs we trust – an innovative paradigm-shift in risk-based chemicals management for globally harmonized protection goals

2024-5-9

Regulation of carboxylesterases and its impact on pharmacokinetics and pharmacodynamics: an up-to-date review

2024-5-6

Cephalosporins with warfarin increase the risk of bleeding: myth or fact?

2024-5-3